StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Macquarie

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byMacquarieHorizon: 1 year11 Aug 2026via NDTV Profit

Entry₹1,119Inferred
Target₹1,285
Total upside +14.83%
Stop lossNot given
CMP₹1,125.4Just now
Active+0.57%+14.18%upside left 10 mo left
Follow Macquarie for new calls(100% target hit, 14 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 6 other Long-term calls on ZYDUSLIFESee 264 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 3:05 pm IST
41 supporting16 neutral9 opposing
Supports the BUY call (41)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·22 Oct · today

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·22 Oct · yesterday

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · yesterday

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 2d ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 2d ago

(opens in new tab)
Neutral / worth noting (16)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 12 days

(opens in new tab)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 3w ago

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (9)

Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations

NewsCnbc-Tv18·13 Oct · 1w ago

(opens in new tab)

The USFDA concluded an inspection of Zydus Lifesciences' Moraiya manufacturing plant with 5 observations, which the company intends to address.

NSE · Press Release·13 Oct · 1w ago

(opens in new tab)

The USFDA concluded an inspection of the company's Moraiya manufacturing plant with 5 observations.

BSE · Company Update·13 Oct · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·12 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Macquarie

Every call and its outcome